Incyte Corporation
Denton Sheila A. Files Incyte (INCY) Form 4 - November 17, 2025
Transactions
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Denton Sheila A. | 2025-11-17 | Sell | 278 | $0.00 | $0.00 | Direct |
| Denton Sheila A. | 2025-11-17 | Buy | 278 | $64.25 | $17.9K | Direct |
| Denton Sheila A. | 2025-11-17 | Sell | 278 | $104.36 | $29.0K | Direct |
Track INCY insider activity
Get alerts when Incyte Corporation executives trade their shares.
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. With a focus on oncology and inflammation, Incyte aims to address significant unmet medical needs through its robust portfolio of proprietary compounds. The company's flagship product, a therapeutic for certain types of blood cancers, underscores its pivotal role in cancer treatment paradigms. Incyte also invests heavily in research and development, maintaining a pipeline of next-generation treatments in various stages of clinical trials. Having established strategic partnerships with leading global pharmaceutical companies, Incyte leverages collaborative efforts to enhance its research capabilities and market presence. Headquartered in Wilmington, Delaware, Incyte Corporation is a key player in the biopharmaceutical sector, significantly contributing to advancements in medical science and patient care through its commitment to innovation and therapeutic excellence.
Official SEC Documents